Human Trial Results Show Excellent Safety Data, From Geovax's DNA/MVA AIDS Vaccines
Fri, 09 Feb 2007 09:00 AM EST
... GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company, today reported successful early results from two ongoing AIDS prevention Phase I human vaccine trials. Results from the first low dose trial indicate a good safety profile as well as positive immune responses in human volunteers receiving 1/10th dose of GeoVax's AIDS vaccine. [click link for full article] ...
Related Topics
- Vaccines & Immunizations
- Data & Statistics
- Chemical Safety
- Safety
- Clinical Trials
- Data Analysis
- Hearing Aids
- Factor IX
- HIV/AIDS & STDs
- Acquired Immune Deficiency Syndrome
- National Data
- Food Safety
- Drug Safety
- Fire Safety
- Child Safety
- Sports Safety
- Electrical Safety
- Workplace Safety & Health
- Safety (General)
- Traffic Safety

Not Signed In -


